ADMA Biologics Stock

ADMA Biologics EBIT

The EBIT of ADMA Biologics (ADMA) as of Aug 21, 2026 is 191.44 M USD. In the previous year, EBIT was 138.98 M USD — a change of 37.75% (higher).

EBIT

191.44 MUSD

YoY

37.75%

Last updated:

In 2026, ADMA Biologics's EBIT was 191.44 M USD, a 37.75% increase from the 138.98 M USD EBIT recorded in the previous year.

The ADMA Biologics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
21.63 base
Jan 1, 2024
138.98 base
Jan 1, 2025
191.44 base
Jan 1, 2026 (e)
-36.28 base
Jan 1, 2027 (e)
-42.77 base
Jan 1, 2028 (e)
-49.43 base
Jan 1, 2029 (e)
-56.82 base
Jan 1, 2030 (e)
-64.68 base
YEAREBIT (M USD)
2030 est -64.68
2029 est -56.82
2028 est -49.43
2027 est -42.77
2026 est -36.28
2025 191.44
2024 138.98
2023 21.63
2022 -46.63
2021 -58.63
2020 -64.05
2019 -40.09
2018 -60.22
2017 -40.53
2016 -17.28
2015 -15.51
2014 -16.02
2013 -15.04
2012 -7.91
2011 -0.03
2010 -0.02
2009 -20.01
2008 -24.89
2007 -29.69
2006 -29.69
Access this data via the Eulerpool API

ADMA Biologics Revenue

ADMA Biologics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
258.22 M USD
21.63 M USD
-28.24 M USD
Jan 1, 2024
426.45 M USD
138.98 M USD
197.67 M USD
Jan 1, 2025
510.17 M USD
191.44 M USD
146.93 M USD
Jan 1, 2026 (e)
535.35 M USD
-36.28 M USD
195.12 M USD
Jan 1, 2027 (e)
700.32 M USD
-42.77 M USD
240.62 M USD
Jan 1, 2028 (e)
728.06 M USD
-49.43 M USD
343.68 M USD
Jan 1, 2029 (e)
836.93 M USD
-56.82 M USD
363.27 M USD
Jan 1, 2030 (e)
952.62 M USD
-64.68 M USD
434.30 M USD

ADMA Biologics Margins

ADMA Biologics stock margins

The ADMA Biologics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ADMA Biologics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ADMA Biologics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
34.44 %
8.38 %
-10.94 %
Jan 1, 2024
51.48 %
32.59 %
46.35 %
Jan 1, 2025
57.39 %
37.53 %
28.80 %
Jan 1, 2026 (e)
57.39 %
-6.78 %
36.45 %
Jan 1, 2027 (e)
57.39 %
-6.11 %
34.36 %
Jan 1, 2028 (e)
57.39 %
-6.79 %
47.21 %
Jan 1, 2029 (e)
57.39 %
-6.79 %
43.41 %
Jan 1, 2030 (e)
57.39 %
-6.79 %
45.59 %

ADMA Biologics Stock analysis

What does ADMA Biologics do? ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market. ADMA Biologics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing ADMA Biologics's EBIT

ADMA Biologics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ADMA Biologics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ADMA Biologics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ADMA Biologics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ADMA Biologics stock

EBIT of ADMA Biologics is 191.44 M USD in 2026.

EBIT of ADMA Biologics changed from 138.98 M USD to 191.44 M USD, representing a 37.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT ADMA Biologics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's ADMA Biologics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — ADMA Biologics

All Key Metrics — ADMA Biologics